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I. GENERAL INTRODUCTION 
Major depressive disorder (MDD) is also amongst the most severe and 
debilitating of the psychiatric illnesses. Almost one million lives are lost annually due 
to suicide, which translates to 3000 deaths daily. Although antidepressants are 
generally effective in the treatment of MDD, it can still take several weeks before 
patients achieve full therapeutic benefit. Additionally, approximately two-thirds of 
these patients fail to respond to conventional antidepressant agents and for those that 
do, there is a high rate of relapse.  
The fast-acting antidepressant effects of the N-methyl-D-aspartate (NMDA) 
receptor antagonist, ketamine, have attracted serious attention after it was found that a 
single sub-anesthetic dose (0.5 mg/kg) of ketamine elicited a rapid antidepressant 
effect within 1-2 hours, in depressed patients, including those with treatment-resistant 
depression and treatment-resistant bipolar depression.However, a great limitation for 
ketamine widely used in clinical is mainly due to its severe psychotomimetic side 
effects and abuse liability.  
Ketamine (or RS-ketamine) is a racemic mixture containing equal parts of 
R-ketamine and S-ketamine. S-ketamine has an approximately 4-fold greater affinity 
for the NMDA receptor than the R-ketamine. Furthermore, S-ketamine shows an 
approximately 3-4 fold greater anesthetic potency and greater undesirable 
psychotomimetic side effects, relative to R-ketamine. Collectively, these findings lend 
weight to the general acceptance that the anesthetic and psychotomimetic actions of 
ketamine are mediated primarily via the blockade of NMDA receptors 
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Therefore, this study consists of two parts: I. To compare the two stereoisomers 
of ketamine in the social defeat stress and learned helplessness models of depression, 
and to examine the effects of these stereoisomers on brain-derived neurotrophic factor 
(BDNF)-TrkB signaling, and synaptogenesis in selected brain regions, and investigate 
the action of these stereoisomers on a profile of side effects, including 
psychotomimetic effects and drug abuse potential; II. To examine whether repeated 
intermittent administration of ketamine enantiomers could affect 
PV-immunoreactivity in the mouse brain. 
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II. CHARPTER I 
BACKGROUND 
As well as being the most prevalent, major depressive disorder (MDD) is also 
amongst the most severe and debilitating of the psychiatric illnesses. The World 
Health Organization estimates that more than 350 million individuals of all ages 
suffer from depression.
1
 Almost one million lives are lost annually due to suicide, 
which translates to 3000 deaths daily.
1
 Although antidepressants are generally 
effective in the treatment of MDD, it can still take weeks before patients feel the full 
therapeutic benefit. Additionally, approximately two-thirds of these patients fail to 
respond to pharmacotherapy and for those that do, there is a high rate of relapse.
2
 This 
highlights the unmet need for therapeutic agents with a rapid onset of action, 
particularly for patients who do not respond to current antidepressants, many of whom 
are at an increased risk of suicide.
3
 In this setting, the glutamatergic system represents 
a promising therapeutic target for MDD.
4-9
 
Over the past decade, the fast-acting antidepressant effects of the 
N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, represent one of the 
most attractive discoveries in the field of psychiatry.
3,10,11
 A sub-anesthetic dose (0.5 
mg/kg) of ketamine confers a rapid antidepressant benefit in depressed patients,
12
 
including treatment-resistant depression and treatment-resistant bipolar 
depression.
13-16
 Ketamine elicits its rapid antidepressant effect within a couple of 
hours, and this effect can be sustained for up to two weeks in some patients. Crucially, 
ketamine is reported to exert rapid effects against suicidal ideation.
17-19
 Recent 
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meta-analyses support the rapid therapeutic action of ketamine in treatment-resistant 
patients.
20-22
  
Ketamine (or RS-ketamine) is a racemic mixture containing equal parts of 
R-ketamine and S-ketamine. S-ketamine has an approximately 4-fold greater affinity 
for the NMDA receptor than the R-ketamine.
10
 Furthermore, S-ketamine shows an 
approximately 3-4 fold greater anesthetic potency and greater undesirable 
psychotomimetic side effects, compared with R-ketamine.
10,23
 These findings lend 
weight to the general acceptance that the anesthetic and psychotomimetic actions of 
ketamine are mediated primarily via the blockade of NMDA receptors.
10,23,24
 In the 
depression model after neonatal dexamethasone exposure, we reported that 
R-ketamine showed greater potency and longer lasting antidepressant effects than 
S-ketamine,
25
 indicating that R-ketamine may be a potent and safe antidepressant 
relative to S-ketamine.
26, 27
 
The purpose of this study was to compare the two stereoisomers of ketamine in 
the social defeat stress and learned helplessness models of depression. In addition, we 
examined the effects of these stereoisomers on brain-derived neurotrophic factor 
(BDNF)-TrkB signaling, and synaptogenesis in selected brain regions, since these 
may be implicated in ketamine’s antidepressant effects.9,28-33 Finally, we examined the 
action of these stereoisomers on a profile of side effects, including psychotomimetic 
effects and drug abuse potential. 
MATERIALS AND METHODS 
Animals 
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Male adult C57BL/6 mice, aged 8 weeks (body weight 20–25g, Japan SLC, Inc., 
Hamamatsu, Japan) and male adult CD1 (ICR) mice, aged 13–15 weeks (body weight 
>40g, Japan SLC, Inc., Hamamatsu, Japan) were used for social defeat stress model. 
Male Sprague-Dawley rats (200–230g, 7-week olds, Charles River Japan, Co., Tokyo, 
Japan) were used for learned helplessness (LH) model. Animals were housed under 
controlled temperatures and 12 hour light/dark cycles (lights on between 07:00–19:00 
h), with ad libitum food (CE-2; CLEA Japan, Inc., Tokyo, Japan) and water. This 
study was carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health. The 
protocol was approved by the Chiba University Institutional Animal Care and Use 
Committee. 
Materials 
R-ketamine hydrochloride and S-ketamine hydrochloride were prepared by 
recrystallization of RS-ketamine (Ketalar
®
, ketamine hydrochloride, Daiichi Sankyo 
Pharmaceutical Ltd., Tokyo, Japan) and D-(-)-tartaric acid (or L- (+)-tartaric acid), as 
described previously.
34
 The purity of these stereoisomers was determined by a 
high-performance liquid chromatography (CHIRALPAK
®
 IA, Column size: 250 x 4.6 
mm, Mobile phase: n-hexane/dichloromethane/diethylamine (75/25/0.1), Daicel 
Corporation, Tokyo, Japan). NBQX, 
2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (Catalog 
number: 0373, Tocris Bioscience, Bristol, UK, 10 mg/kg) was dissolved in saline. 
ANA-12, N2-(2-{[(2-oxoazepan-3-yl) 
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amino]carbonyl}phenyl)benzo[b]thiophene-2-carboxamide (Catalog number: 
BTB06525SC, Maybridge, UK, 0.5 mg/kg) was prepared in vehicle of 1% 
dimethylsulfoxide (DMSO) in phosphate-buffered saline. The dose of ketamine, 
NBQX, and ANA-12 was selected as reported previously.
34-40
 Other reagents were 
purchased commercially. 
Social defeat stress model 
The procedure of social defeat stress was performed as previously reported.
41,42
 Every 
day the C57BL/6 mice were exposed to a different CD1 aggressor mouse for 10 min, 
total for 10 days. When the social defeat session ended, the resident CD1 mouse and 
the intruder mouse were housed in one half of the cage separated by a perforated 
Plexiglas divider to allow visual, olfactory, and auditory contact for the remainder of 
the 24-h period. At 24 h after the last session, all mice were housed individually. On 
day 11, a social avoidance test was performed to identify subgroups of mice that were 
susceptible and unsusceptible to social defeat stress. This was accomplished by 
placing mice in an interaction test box (42×42 cm) with an empty wire-mesh cage 
(10×4.5 cm) located at one end. The movement of the mice was tracked for 2.5 min, 
followed by 2.5 min in the presence of an unfamiliar aggressor confined in the 
wire-mesh cage. The duration of the subject’s presence in the “interaction zone” 
(defined as the 8-cm-wide area surrounding the wiremesh cage) was recorded by a 
stopwatch. The interaction ratio was calculated as time spent in an interaction zone 
with an aggressor / time spent in an interaction zone without an aggressor. An 
interaction ratio of 1 was set as the cutoff: mice with scores < 1 were defined as 
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“susceptible” to social defeat stress and those with scores ≥ 1 were defined as 
“unsusceptible”.42 Only susceptible mice was been used in the experiments. 
Learned helplessness (LH) stress model 
LH paradigm was performed as reported previously.
36,43,44
 To create the LH paradigm, 
rats are initially exposed to uncontrollable stress. When the rat is later placed in a 
situation in which shock is controllable (escapable), it not only fails to acquire the 
escape responses, but also often makes no efforts to escape the shock at all. LH 
behavioral tests were performed using the Gemini Avoidance System (San Diego 
Instruments, San Diego, CA). This apparatus was divided into two compartments by a 
retractable door. On day 1 and 2, rats were subjected to 30 inescapable electric foot 
shock (0.65 mA, 30 sec duration, at random intervals (mean 30 sec, average 18-42 
sec)). On day 3, a two-way conditioned avoidance test was performed as a post-shock 
test to determine if the rats would show the predicted escape deficits. This screening 
session consisted of 30 trials in which electric foot shocks (0.65 mA, 6 sec duration, at 
random intervals (mean 30 sec, average 18-42 sec)) were preceded by a 3 sec 
conditioned stimulus tone that remained on until the shock was terminated. 
Subsequently, saline (1 ml/kg), R-ketamine (20 mg/kg) or S-ketamine (20 mg/kg) was 
administered i.p. into control and LH rats. On day 8, a two-way conditioned 
avoidance test was performed. This test session consisted of 30 trials in which electric 
foot shocks (0.65 mA, 30 sec duration, at random intervals (mean 30 sec, average 
18-42 sec)) were preceded by a 3 sec conditioned stimulus tone that remained on until 
the shock was terminated. The numbers of escape failures and the latency to escape in 
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each 30 trial were recorded by the Gemini Avoidance System. 
Behavioral tests of antidepressant effects 
Behavioral tests of antidepressant effects including locomotion, tail suspension test 
(TST), forced swimming test (FST) and sucrose preference test (SPT) were performed 
as reported previously.
34,37
 Behavioral tests were performed as reported previously 
(34, 37). Locomotion: the locomotor activity was measured by an animal movement 
analysis system SCANETMV-40 (MELQUEST Co., Ltd., Toyama, Japan), the mice 
were placed in experimental cages (length × width × height: 560 × 560 × 330 mm). 
The cumulative exercise was recorded for 60 minutes. Cages were cleaned between 
testing session.  
Tail suspension test (TST): A small piece of adhesive tape placed approximately 2 cm 
from the tip of the tail for mouse. A single hole was punched in the tape and mice were 
hung individually, on a hook. The immobility time was recorded for 10 minutes. Mice 
were considered immobile only when they hung passively and completely motionless.  
Forced swimming test (FST): The FST was tested by an automated forced-swim 
apparatus SCANETMV-40 (MELQUEST Co., Ltd., Toyama, Japan). The mice were 
placed individually in a cylinder (diameter: 23 cm; height: 31 cm) containing 15 cm of 
water, maintained at 23 ± 1℃. Immobility time from activity time as (total) – (active) 
time was calculated by the apparatus analysis software. The immobility time for 
mouse was recorded for 6 minutes. 
Sucrose preference test (SPT): Mice were exposed to water and 1% sucrose 
solution for 48 h, followed by 4 hours of water and food deprivation and a 1 hour 
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exposure to two identical bottles, one is water, and another is 1% sucrose solution. 
The bottles containing water and sucrose were weighed before and at the end of this 
period and the sucrose preference was determined. 
Behavioral tests of side effects 
Behavioral tests of side effects such as locomotion, prepulse inhibition (PPI) test and 
conditioned place preference (CPP) test were performed as reported previously.
45-47
 
Locomotion: After habituation (60 min) in the cage, saline (10 ml/kg), R-ketamine (5, 
10 or 20 mg/kg), or S-ketamine (5, 10 or 20 mg/kg) was injected i.p. into mice. 
Locomotor activity was measured using an animal movement analysis system 
(SCANET MV-40, Melquest, Toyama, Japan). The system consisted of a rectangular 
enclosure (560 x 560 mm). The side walls (height, 60 mm) of the enclosure were 
equipped with 144 pairs of photosensors located at 6-mm intervals at a height of 30 
mm from the bottom edge. An animal was placed in the observation cage 120 minutes 
from a single dose of saline or ketamine isomers. A pair of photosensors was scanned 
every 0.1 second to detect the animal’s movements. The intersection of paired 
photosensors (10 mm apart) in the enclosure was counted as one unit of locomotor 
activity. Data collected for 180 minutes were used in this study.  
Prepulse inhibition (PPI) test: The mice were tested for their acoustic startle 
reactivity (ASR) in a startle chamber (SR-LAB; San Diego Instruments, San Diego, 
CA, USA) using the standard methods described previously (45, 46). The test sessions 
were begun after an initial 10-min acclimation period in the chamber. The mice were 
subjected to one of six trials: (1) pulse alone, as a 40 ms broadband burst; a pulse (40 
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ms broadband burst) preceded by 100 ms with a 20 ms prepulse that was (2) 4 dB, (3) 
8 dB, (4) 12 dB, or (5) 16 dB over background (65 dB); and (6) background only (no 
stimulus). The amount of PPI was expressed as the percentage decrease in the 
amplitude of the startle reactivity caused by presentation of the prepulse (% PPI). 
Saline (10 ml/kg), or R-ketamine (or S-ketamine)(5, 10 or 20 mg/kg) was 
administered i.p. 20 min (including the 10-min acclimation period) before the 
machine records. The PPI test lasted 20 min in total. 
Conditioned place preference (CPP) test: The place conditioning paradigm (CPP; 
Brain Science Idea Inc., Osaka, Japan) was used for studying ketamine-induced 
rewarding effects, as reported previously (47). The test mouse was allowed to move 
freely between transparent and black boxes for a 15 min session once a day, for 3 days 
(days 1–3) as preconditioning. On day 3, the time spent in each box was measured. 
There was no significant difference between time spent in the black compartment with 
a smooth floor and the white compartment with a textured floor, indicating that there 
was no place preference before conditioning. On days 4, 6, and 8, saline (10 ml/kg), 
or RS-ketamine (10 mg/kg)(or R-ketamine, S-ketamine (5, 10 or 20 mg/kg)) was i.p. 
administered, and then mice were confined to either the transparent or black box for 
30 min. On days 5, 7, and 9, mice were given saline and placed in the opposite 
ketamine-conditioning box for 30 min. On day 10, the post-conditioning test was 
performed without drug treatment, and the time spent in each box was measured for 
15 min. A counterbalanced protocol was used in order to nullify any initial preference 
by the mouse. The CPP score was designated as the time spent in the 
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drug-conditioning sites, minus the time spent in the saline-conditioning sites. 
Golgi staining 
Golgi staining was performed using the FD Rapid GolgiStain
TM
 Kit (FD Neuro 
Technologies, Inc., Columbia, MD, USA), following the manufacturer's instructions. 
Golgi staining was performed using the FD Rapid GolgiStain
TM
 Kit (FD Neuro 
Technologies, Inc., Columbia, MD, USA), following the manufacturer's instructions, 
as previously reported (34, 36, 60). Mice were deeply anesthetized with sodium 
pentobarbital, and brains were removed from the skull and rinsed in double distilled 
water. Brains were immersed in the impregnation solution, made by mixing equal 
volumes of Solution A and B, overnight and then stored in fresh solution, for 2 weeks 
in the dark. Brains were transferred into Solution C overnight and then stored in fresh 
solution at 4°C for 1 week, in the dark. Coronal brain sections (100 µm thickness) 
were cut on a cryostat (3050S, Leica Microsystems AG, Wetzlar, Germany), with the 
chamber temperature set at -20°C. Each section was mounted in Solution C, on 
saline-coated microscope slides. After absorption of excess solution, sections were 
dried naturally, at room temperature. Dried sections were processed following the 
manufacturer's instructions. Briefly, images of dendrites within medial prefrontal 
cortex (mPFC), hippocampal CA1, CA3, and dentate gyrus (DG), nucleus accumbens 
(NAc)-core, NAc-shell, and striatum were captured using a 100× objective with a 
Keyence BZ-9000 GenerationⅡmicroscope (Osaka, Japan). Spine density in these 
regions was counted as previously reported (34, 36, 60). For spine density 
measurements, all clearly evaluable areas containing 50-100 µm of secondary 
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dendrites from each imaged neuron were used. To determine relative spine density, 
spines on multiple dendritic branches from a single neuron were counted to obtain an 
average spine number per 10 µm. For spine number measurements, only spines that 
emerged perpendicular to the dendritic shaft were counted. Two to three neurons per 
section, three sections per animal were analyzed. The average value for each region, 
in each individual was obtained. These individual averages were then combined to 
yield a grand average for each region. 
Western blot analysis 
Western blot analysis was performed as reported previously (for details, see 
Supplement 1).
34,36
 Mice were killed by cervical dislocation and brains were rapidly 
removed from the skull. Approximately 1-mm-thick coronal sections were cut and 
bilateral tissue punches of PFC, NAc, CA1, CA3 and dentate gyrus (DG) of the 
hippocampus were dissected on ice using a SZ-LED Kenis light microscope (Osaka, 
Japan), and stored at -80°C. Basically, tissue samples were homogenized in Laemmli 
lysis buffer. Aliquots (10 μg) of protein were measured using the DC protein assay kit 
(Bio-Rad, Hercules, CA), and incubated for 5 min at 95 °C, with an equal volume of 
125 mM Tris/HCl, pH 6.8, 20% glycerol, 0.1% bromophenol blue, 10% 
β-mercaptoethanol, 4% sodium dodecyl sulfate, and subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis, using 10% mini-gels (Mini-PROTEAN® 
TGX™ Precast Gel; Bio-Rad, CA, USA). Proteins were transferred onto 
polyvinylidenedifluoride (PVDF) membranes using a Trans Blot Mini Cell (Bio-Rad). 
For immunodetection, the blots were blocked with 2% BSA in TBST (TBS + 0.1% 
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Tween-20) for 1 h at room temperature (RT), and kept with primary antibodies 
overnight at 4°C. The following primary antibodies were used: BDNF (1: 200, Santa 
Cruz Biotechnology, Inc., CA, USA), phosphor-TrkB (Tyr 706) (1:200, Santa Cruz 
Biotechnology, Inc., CA), TrkB (80E3) (1:1000, Cell Signaling Technology, MA), 
and AMPA glutamate receptor 1 (GluA1) (1 µg/ml, Abcam, Cambridge, MA). The 
next day, blots were washed three times in TBST and incubated with horseradish 
peroxidase conjugated anti-rabbit antibody (1:5000) 1 hour, at RT. After final three 
washes with TBST, bands were detected using enhanced chemiluminescence (ECL) 
plus the Western Blotting Detection system (GE Healthcare Bioscience). The blots 
then were washed three times in TBST and incubated with the primary antibody 
directed against β-actin (1:10000, Sigma-Aldrich Co, Ltd, St Louis, MO). Images 
were captured with a Fuji LAS3000-mini imaging system (Fujifilm, Tokyo, Japan), 
and immunoreactive bands were quantified. 
Parvalbumin (PV)-immunohistochemistry 
PV-immunohistochemistry was performed as previously reported.
48
 Saline (10 ml/kg), 
R-ketamine (10 mg/kg), or S-ketamine (10 mg/kg) was administered i.p. into mice. 
Thirty min after injection, mice were anesthetized with sodium pentobarbital (50 
mg/kg) and perfused transcardially with 10 mL of isotonic saline, followed by 40 mL 
of ice-cold, 4% paraformaldehyde in 0.1%M phosphate buffer (pH 7.4). Brains were 
removed from the skulls and postfixed overnight at 4℃ in the same fixative. For the 
PV-immunohistochemistry, 50 μm-thick serial, coronal sections of brain tissue were 
cut in ice-cold, 0.001M phosphate buffered saline (pH 7.5) using a vibrating blade 
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microtome (VT1000s, Leica Microsystems AG, Wetzlar, Germany). Free-floating 
sections were treated with 0.3% H2O2 in 50 mM Tris-HCL saline (TBS) for 30 min 
and were blocked in TBS containing 0.2% Triton X-100 (TBST) and 1.5% normal 
serum for 1 h at room temperature. The samples ware then incubated for 24 h at 4℃ 
with rabbit polyclonal anti-parvalbumin (PV) antibody (1:2,500, Swant, Bellinzona, 
Switzerland). The sections were washed three times in TBS and then processed using 
the avidin-biotin-peroxidase method (Vectastain Elite ABC, Vector Laboratories, Inc., 
Burlingame, CA, USA). Sections ware incubated for 3 min in a solution of 0.25 
mg/mL DAB containing 0.01% H2O2. Then, sections were mounted on gelatinized 
slides, dehydrated, cleared, and cover slipped under PermountⓇ(Fisher Scientific, Fair 
Lawn, NJ, USA). The sections were imaged, and the staining intensity of PV 
immunoreactivity in the mPFC, hippocampus (CA1, CA3, DG) was analyzed using a 
light micro-scope equipped with a CCD camera (Olymups IX70) and the SCION 
IMAGE software package. Images of sections within mPFC and hippocampal CA1, 
CA3, DG regions were captured using a 100× objective with a Keyence BZ-9000 
GenerationⅡmicroscope (Osaka, Japan). 
Statistical analysis 
The data show as the mean ± standard error of the mean (S.E.M.). Analysis was 
performed using PASW Statistics 20 (formerly SPSS Statistics; SPSS). Comparisons 
between groups were performed using the one-way analysis of variance (ANOVA) or 
two-way ANOVA, followed by post-hoc Fishers Least Significant Difference (LSD) 
test. The PPI data were analyzed using multivariate analysis of variance (MANOVA), 
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followed by post-hoc Fisher LSD test. The P-values of less than 0.05 were considered 
statistically significant. 
RESULTS 
R-ketamine shows greater potency and longer lasting antidepressant effects than 
S-ketamine in the social defeat stress model 
First, we examined the effects of R-ketamine (10 mg/kg) and S-ketamine (10 mg/kg) 
on the social defeat stress model of depression (Fig. 1A). Both stereoisomers of 
ketamine significantly attenuated the reduced sucrose preference seen in depressed 
mice, one day after a single dose. The anti-anhedonia effect of R-ketamine was 
significantly more potent than that of S-ketamine (Fig. 1B). There were no differences 
in locomotion among the four groups (Fig. 1C). In the tail suspension test (TST) and 
forced swim test (FST), both R-ketamine and S-ketamine significantly reduced the 
typically increased immobility time displayed by depressed mice, two days after a 
single dose. The antidepressant effect of R-ketamine was also significantly more 
potent relative to that of S-ketamine (Fig. 1D and 1E). Anti-anhedonia and 
antidepressant effects of R-ketamine were significantly more potent than those of 
S-ketamine, although both stereoisomers showed antidepressant effects six to seven 
days after a single dose (Fig. 1F, 1G, and 1H). These data suggest a greater 
therapeutic potency for R-ketamine in the social defeat stress model. 
Antidepressant effects of R-ketamine, but not S-ketamine, in the rat learned 
helplessness model 
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Figure 1. Antidepressant effects of R-ketamine and S-ketamine in social defeat stress and 
learned helplessness (LH) models of depression. (A): The schedule of social defeat stress model 
and behavioral tests after treatment. (B): One % sucrose preference test (SPT) was performed 1 d 
after a single dose of saline, R-ketamine (10 mg/kg) or S-ketamine (10 mg/kg)(one-way ANOVA, 
F3,42 = 11.05, P = 0.002). (C-E): Behavioral tests, including locomotion (LMT; F3,35 = 0.038, P = 
0.99), tail suspension test (TST; F3,34=12.046, P < 0.001) and forced swimming test (FST; 
F3,34=13.235, P < 0.001), were performed 2 d after a single dose. (F): SPT was performed 6 d after 
a single dose (F3,34 = 9.974, P < 0.001). (G, H): TST (F3,32 = 12.019, P < 0.001) and FST (F3,32 = 
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14.479, P < 0.001) were performed 7 d after a single dose. Data are shown as mean ± S.E.M. (n = 
8-11) *P < 0.05, **P < 0.01, ***P < 0.001. (I): The schedule of learned helplessness (LH) model 
and behavioral tests after treatment. (J, K): The failure of LH (one-way ANOVA, F2,15 = 3.903, P = 
0.043) and the escape latency of LH (F2,15 = 4.317, P = 0.033) were measured 5 d after a single 
dose of saline, R-ketamine (20 mg/kg) or S-ketamine (20 mg/kg). Data are shown as mean ± S.E.M. 
(n = 6) *P < 0.05. 
In the rat learned helplessness (LH) model of depression, vehicle (10 ml/kg), 
R-ketamine (20 mg/kg) or S-ketamine (20 mg/kg) were administered intraperitoneally 
(i.p) into rats. Behavioral tests were performed five days after a single dose of test 
compound (Fig. 1I). R-ketamine, but not S-ketamine, significantly (P < 0.05) 
attenuated the failure of LH and escape latency of LH (Fig. 1J and 1K). These data 
imply an antidepressant effect for R-ketamine, but not S-ketamine in the rat LH 
model. 
Effects of R-ketamine and S-ketamine on alterations in brain dendritic spine 
density induced by social defeat stress 
Previous reports demonstrated that the depression-like phenotype brought on by stress 
and inflammation causes alterations in dendritic spine density in the medial prefrontal 
cortex (mPFC), CA3, and dentate gyrus (DG) of the hippocampus, and nucleus 
accumbens (NAc).
34-36
 In this study, we examined whether the two stereoisomers 
could affect alterations in the dendritic spines of the prelimbic (PrL) and infralimbic 
(IL) regions of mPFC, shell and core of the NAc, striatum, and CA1, CA3, DG of the 
hippocampus, after social defeat stress. We found significant differences in the PrL of 
(10 mg/kg) and S-ketamine (10 mg/kg), significantly attenuated the reduced spine 
density typically seen in the PrL, CA3, and DG from depressed mice, eight days after 
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Figure 2. Effects of R-ketamine and S-ketamine on alterations in dendritic spine density in 
the brain regions after social defeat stress. Representative photomicrographs of Golgi-Cox 
stained pyramidal neurons in the PrL of mPFC, IL of mPFC, NAc core, NAc shell, striatum, CA1, 
CA3 and DG of hippocampus from animals of each group. Scale bar =10 µm. PrL (one-way 
ANOVA, F3,20 = 8.123, P = 0.001). IL (F3,20 = 0.528, P = 0.668). NAc core (F3,20 = 6.318, P = 
0.003). NAc shell (F3,20 = 6.332, P = 0.003). Striatum (F3,20 = 0.381, P = 0.768). CA1 (F3,20 = 
0.459, P = 0.714). CA3 (F3,20 = 8.448, P = 0.001). DG (F3,20 = 5.546, P = 0.006). Values represent 
the mean ± S.E.M. (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 compared with saline-treated 
group of depressed mice. N.S.: not significant. 
a single dose (Fig. 2A, 2G, 2H). Interestingly, in the DG, R-ketamine conferred a 
significantly (P < 0.01) more potent effect than S-ketamine (Fig. 2H). In contrast, 
social defeat stress significantly increased dendritic spine density in the NAc core (P 
< 0.05) and NAc shell (P < 0.01) (Fig. 2C, 2D). Neither R-ketamine nor S-ketamine 
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altered spine density in the NAc of depressed mice. These findings implicate the PrL 
of mPFC, CA3 and DG, but not NAc, in the mechanistic action of ketamine, since 
synaptogenesis is thought to be involved in the action of antidepressants. 
Role of AMPA receptors and BDNF-TrkB signaling in the antidepressant action 
of ketamine isomers 
Since the α-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid (AMPA) receptor 
plays a role in ketamine’s antidepressant activity,49 we examined the effects of NBQX, 
an AMPA receptor antagonist, on R-ketamine and S-ketamine (Fig. 3A). Pretreatment 
with NBQX (10 mg/kg, i.p., 30 min) significantly blocked the antidepressant effects 
of R-ketamine (10 mg/kg) and S-ketamine (10 mg/kg) in the social defeat stress model 
(Fig. 3C-3E). These findings highlight a possible role for AMPA receptors in the 
antidepressant mechanisms of both stereoisomers. 
Since BDNF-TrkB signaling is a putative pathway in ketamine’s therapeutic 
mode of action,
31,33
 we examined the effects of ANA-12, a TrkB antagonist, on the 
activity of R and S-ketamine (Fig. 3F). Co-treatment with ANA-12 (0.5 mg/kg, i.p.) 
significantly blocked the antidepressant effects of R-ketamine (10 mg/kg) and 
S-ketamine (10 mg/kg) in the social defeat stress model (Fig. 3H-3J). These findings 
place BDNF-TrkB signaling in the mechanistic pathways of both stereoisomers. 
Effects of R-ketamine and S-ketamine on alterations in BDNF, TrkB 
phosphorylation and synaptogenesis in selected brain regions 
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We performed Western blot analyses of BDNF, TrkB, phosphorylated TrkB (p-TrkB) 
and GluA1 in selected brain regions (PFC, NAc, DG, CA1 and CA3 of the 
hippocampus), seven days after a dose of saline, R-ketamine (10 mg/kg), or 
S-ketamine (10 mg/kg). Social defeat stress significantly decreased levels of BDNF 
protein in the PFC, DG and CA3, but not CA1, while significantly increasing BDNF 
protein in the NAc. Interestingly, both stereoisomers significantly attenuated reduced 
levels of BDNF protein in the PFC, CA3 and DG after social defeat stress, although 
neither affected the increased levels of BDNF protein in the NAc (Fig. 4A). Effects of 
R-ketamine on the reduction of BDNF in CA3 were significantly more potent than 
S-ketamine (Fig. 4A). 
To clarify the role of TrkB phosphorylation in the action of the stereoisomers, we 
performed Western blot analyses of TrkB and p-TrkB, an activated form of TrkB, 
in samples from PFC, NAc, and hippocampus (CA1, CA3, DG). Tissue levels of 
TrkB in the all tested regions did not differ among the four groups (Fig. 4C). Social 
defeat stress significantly decreased the ratio of p-TrkB/TrkB protein in the PFC, CA3 
and DG, but not CA1, while significantly increasing the ratio of p-TrkB/TrkB protein 
in the NAc (Fig. 4B). Furthermore, R-ketamine significantly attenuated the reduced 
ratio of p-TrkB/TrkB protein in PFC, CA3, and DG. R-ketamine conferred a 
significantly greater effect on the ratio of p-TrkB/TrkB protein in the CA3 and DG 
relative to S-ketamine (Fig. 4B). In contrast, R-ketamine and S-ketamine did not alter 
the increased ratio of p-TrkB/TrkB protein in NAc. These findings suggest that  
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Figure 3. Role of AMPA receptor and BDNF-TrkB signaling in the mechanisms of 
antidepressant effect for R-ketamine and S-ketamine. (A): The schedule of social defeat stress 
model and behavioral tests after treatment. NBQX (10 mg/kg), an AMPA receptor antagonist, was 
administered 30 min before saline or R-ketamine (10 mg/kg) (or S-ketamine (10 mg/kg)). 
Behavioral tests, including locomotion (LMT; one-way ANOVA, F5,34 = 0.06, P = 0.997), tail 
suspension test (TST; F5,39 = 14.628, P < 0.001) and forced swimming test (FST; F5,42 = 9.015, P < 
0.001), were performed 1 d after a single dose. Sucrose preference test (SPT) was 7 d after a 
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single dose of saline, R-ketamine (10 mg/kg) or S-ketamine (10 mg/kg)(F5,40 = 11.748, P < 0.001). 
Values represent the mean ± S.E.M. (n = 6-9). *P < 0.05, **P < 0.01, ***P < 0.001. N.S.: not 
significant. (B): The schedule of social defeat stress model and behavioral tests after treatment. 
ANA-12 (0.5 mg/kg), a TrkB antagonist, was co-administered with saline or R-ketamine (10 
mg/kg) (or S-ketamine (10 mg/kg)). Behavioral tests, including locomotion (LMT; one-way 
ANOVA, F5,37 = 0.414, P = 0.836), tail suspension test (TST; F5,33 = 14.044, P < 0.001) and forced 
swimming test (FST; F5,32 = 15.783, P < 0.001), were performed 1 d after a single dose. Sucrose 
preference test (SPT) was 7 d after a single dose of saline, R-ketamine (10 mg/kg) or S-ketamine 
(10 mg/kg)(F5,36 = 11.825, P < 0.001). Values represent the mean ± S.E.M. (n = 6-8). *P < 0.05, 
**P < 0.01, ***P < 0.001. N.S.: not significant. 
BDNF-TrkB signaling in PFC and hippocampus (CA3 and DG) is integral to the 
mechanisms of both stereoisomers. 
Protein levels of GluA1, a subtype of the AMPA receptor, are a marker for 
synaptogenesis.
9,32
 Social defeat stress significantly decreased the levels of GluA1 in 
PFC, CA3, and DG, but not CA1, while significantly increasing GluA1 protein in the 
NAc (Fig. 4D). Furthermore, both stereoisomers significantly attenuated the reduction 
of GluA1 in PFC, CA3, and DG. Both R- and S-ketamine produced similar effects on 
GluA1 protein in the PFC, CA3 and DG (Fig. 4D). In contrast, R-ketamine and 
S-ketamine did not alter the increased levels of GluA1 in NAc (Fig. 4D). 
Behavioral side effects of R-ketamine and S-ketamine 
First, we examined the effects of both stereoisomers on spontaneous locomotion in 
control mice. A single dose of S-ketamine (5, 10 or 20 mg/kg) elevated locomotion in 
mice, in a significant and dose dependent manner, but the hyperactivity quickly 
returned to control levels. In contrast, an administration of R-ketamine (5, 10 or 20 
mg/kg) had no effect on locomotion in mice (Fig. 5A). 
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Figure 4. Effect for R-ketamine and S-ketamine on the BDNF, TrkB phosphorylation, and 
GluA1 in the brain regions. (A): Western blot analysis of BDNF in PFC, NAc, CA1, CA3 and 
DG. PFC (one-way ANOVA, F3,13 = 5.759, P = 0.009). NAc (F3,13 = 3.544, P = 0.045). CA1 (F3,14 
= 0.065, P = 0.978). CA3 (F3,13 = 8.324, P = 0.002). DG (F3,13 = 7.444, P = 0.003). The value was 
expressed as a percentage of that of control mice. Values represent the mean ± S.E.M. (n = 5 or 6). 
*P < 0.05, **P < 0.01. (B, C): Effects of R-ketamine and S-ketamine on changes in 
phosphorylation of TrkB in the mouse brain after social defeat stress. The ratio of p-TrkB to total 
TrkB in the brain regions was shown. PFC (one-way ANOVA, F3,13 = 3.962, P = 0.033). NAc 
(F3,13 = 3.613, P = 0.043). CA1 (F3,14 = 0.05, P = 0.984). CA3 (F3,14 = 6.545, P = 0.005). DG (F3,13 
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= 7.612, P = 0.003). Total levels of TrkB protein in the all regions were not different among the 
four groups. Values represent the mean ± S.E.M. (n = 4 or 5). *P < 0.05, **P < 0.01. N.S.: not 
significant. (D): Western blot analysis of GluA1 in PFC, NAc, CA1, CA3 and DG of the 
hippocampus. PFC (one-way ANOVA, F3,13 = 3.619, P = 0.04). NAc (F3,14 = 7.834, P = 0.003). 
CA1 (F3,14 = 0.060, P = 0.98). CA3 (F3,14 = 5.207, P = 0.013). DG (F3,14 = 5.108, P = 0.014). The 
value was expressed as a percentage of that of control mice. Values represent the mean ± S.E.M. 
(n = 5 or 6). *P < 0.05, **P < 0.01, ***P < 0.001. 
Next, we examined the effects of the stereoisomers on prepulse inhibition (PPI) 
in control mice. A single administration of R-ketamine (5, 10 or 20 mg/kg) did not 
alter PPI in the mice (Fig. 5B). In contrast, a dose of S-ketamine (10 and 20 mg/kg) 
caused significant PPI deficits at 77 dB and 81 dB levels (Fig. 5C). These findings 
suggest that, unlike R-ketamine, S-ketamine may be more prone to cause 
psychotomimetic side effects. 
     The recreational use of ketamine has increased in many parts of the world, and 
its abuse is often associated with harmful physical and psychological consequences.
50 
In this study, we examined the rewarding effects of RS-ketamine (racemate) and the 
two stereoisomers under the conditioned place preference (CPP) test (Fig. 5D). 
RS-Ketamine (10 mg/kg) significantly increased CPP scores in mice (Fig. 5E), while 
R-ketamine (5, 10 or 20 mg/kg) had no effect on CPP scores (Fig. 5F). In contrast, 
S-ketamine (5, 10 or 20 mg/kg) significantly increased CPP scores, in a dose 
dependent manner (Fig. 5G). The data suggest that S-ketamine and RS-ketamine, but 
not R-ketamine, may induce rewarding effects. 
Effects of R-ketamine and S-ketamine on parvalbumin (PV)-positive cells in the 
brain 
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Figure 5. Side effect profiles for S-ketamine, but not R-ketamine, in mice. (A): Effects of 
R-ketamine and S-ketamine on locomotion in control mice. One hour after habituation, saline, 
R-ketamine (5, 10 or 20 mg/kg), or S-ketamine (5, 10 or 20 mg/kg) was administered i.p. into mice. 
Two-way ANOVA analysis revealed significant interactions [drug: F6,125 =6.441, P < 0.001; time: 
F17,125 =138.838, P < 0.001; interaction (drug × time ): 2.814, P < 0.001]. Values represent the 
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mean ± S.E.M. (n=8). **P < 0.01, ***P < 0.001 compared with saline-treated group. (B): Effects 
of R-ketamine (5, 10 or 20 mg/kg) on prepulse inhibition (PPI) test in control mice. The 
MANOVA revealed no significant effect (Wilks lambda = 0.713, P = 0.333). Values represent the 
mean ± S.E.M. (n=8). (C): Effects of S-ketamine (5, 10 or 20 mg/kg) on prepulse inhibition (PPI) 
test in control mice. The MANOVA revealed significant effect (Wilks lambda = 0.554, P = 0.019). 
*P < 0.05, **P < 0.01 compared with saline-treated group. Values represent the mean ± S.E.M. (n 
= 8). (D): The schedule of CPP model and behavioral tests after treatment. (E): RS-Ketamine (10 
mg/kg) significantly (P = 0.0125) increased CPP scores in mice (n = 9). (F): R-Ketamine (5, 10 or 
20 mg/kg) did not increase CPP score (F3,35 = = 0.147, P = 0.931). (G): S-Ketamine (5, 10 or 20 
mg/kg) significantly increased CPP score (F3,34 = 5.441, P = 0.004). Values represent the mean ± 
S.E.M. (n = 9-10). *P < 0.05, **P < 0.01 compared with saline-treated group. 
A reduction in parvalbumin (PV)-positive cells in the brain are associated with 
psychosis and cognitive impairment in schizophrenia.
51,52
 A single administration of 
R-ketamine (10 mg/kg, 30 min) had no effect on the proportion of PV-positive cells in 
any of the tested brain regions (Fig. 6A-6F). In contrast, a single dose of S-ketamine 
(10 mg/kg, 30 min) significantly decreased the proportion of PV-positive cells in the 
PrL region of the mPFC (Fig. 6A, P = 0.006) and DG of the hippocampus (Fig. 6F, P 
< 0.001), but not in other regions (IL region of mPFC, NAc, CA1, CA3) (Fig. 6B-6E). 
DISCUSSION 
In this study, we found R-ketamine to be a more potent and longer lasting 
antidepressant than S-ketamine. The superior potency of R-ketamine’s effects over 
S-ketamine was demonstrated in the social defeat stress model of depression. 
Furthermore, R-ketamine showed antidepressant effects in the rat LH model of 
depression while S-ketamine showed none. To the best of our knowledge, this is the 
first report comparing the antidepressant effects of the ketamine stereoisomers in the 
social defeat stress and LH models of depression. These findings suggest that 
R-ketamine is a more efficacious antidepressant than S-ketamine.  
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Figure 6. Effect of R-ketamine and S-ketamine on PV-positive immunostaining in the brain. 
Mice were perfused 30 min after a single dose of saline, R-ketamine (10 mg/kg) or S-ketamine (10 
mg/kg). Then PV-immunohistochemistry was performed. Representative photomicrographs of 
PV-immunohistochemistry in the PrL (A) and IL (B) of mPFC, NAc (C), CA1 (D), CA3 (E), and 
DG (F) of hippocampus from animals of each group. Scale bar = 10 µm (A-C) or 200 µm (D-F). 
One-way ANOVA revealed significant effects in the PrL (F2,14 = 7.57, P = 0.016) of mPFC and 
DG (F2,15 = 13.834, P < 0.001), but not IL of mPFC (F2,14 = 0.602, P = 0.562), NAc (F2,15 = 0.019, 
P = 0.981), CA3 (F2,15 = 0.015, P = 0.985), CA1 (F2,14 = 0.234, P = 0.795). The data show the 
mean ± SEM (n = 5 or 6). *P < 0.05, ***P<0.001 compared with saline-treated group. NS: not 
significant. 
Accumulating evidence suggests that BDNF-TrkB signaling is key to the 
depression-like phenotype.
53-56
 In this study, we found a marked reduction of BDNF 
protein in the PFC, DG, CA3, but not CA1, of depressed mice after social defeat 
stress, consistent with recent results from the inflammation model and rat LH 
model.
34,36
 In contrast, we also found that social defeat stress induced a marked 
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increase in BDNF protein within the NAc, also in keeping with recent papers on the 
inflammation and LH models.
34,36
 Furthermore, we found that social defeat stress 
caused decreased phosphorylation of TrkB in the PFC, CA3, and DG, and increased 
phosphorylation of TrkB in the NAc. Thus, it is probable that social defeat stress 
promoted decreased BDNF-TrkB signaling in PFC and hippocampus (CA3 and DG), 
while increasing signals in the NAc, inducing depression-like behavior in rodents. 
This study also highlighted that both R-ketamine and S-ketamine significantly 
attenuated reduced BDNF level in the PFC, CA3 and DG, although these drugs did 
not affect the increased BDNF levels in the NAc of depressed mice. Interestingly, 
ANA-12, a TrkB antagonist, was able to block the antidepressant effects of both 
stereoisomers, suggestive of a role for BDNF-TrkB signaling in ketamine’s 
antidepressant mechanism. Given the role of BDNF-TrkB signaling in the 
depression-like phenotype,
53-56
 it is likely that both stereoisomers exert antidepressant 
effects by normalizing BDNF levels in the PFC and hippocampus (CA3, and DG), but 
not NAc. Further detailed studies examining the effects of ketamine on BDNF-TrkB 
signaling are necessary. 
Tracking dendritic morphology, we detected opposing changes in spine density 
between the mPFC, hippocampus, and NAc. The reduced spine density detected in the 
PrL of mPFC, CA3 and DG, is similar to the findings seen in rodents in the 
unpredictable chronic mild stress, inflammation, and LH models.
34,36,57
 In contrast, we 
found increased spine density in the NAc of depressed mice under social defeat stress, 
consistent with results from the inflammation, and LH models.
34,36
 Interestingly, both 
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stereoisomers of ketamine attenuated the reduction in spine density in the PrL, but not 
IL region, of mPFC, CA3, and DG, although they did not alter increased spine density 
in the core and shell of the NAc. A recent electrophysiology study demonstrated that 
ketamine enhanced corticotropin-releasing hormone (CRF)-induced excitatory 
postsynaptic currents in conjunction with an increased density of basal dendritic 
synaptic spines in the PrL, but not IL, of mPFC.
58
 Considering that synaptogenesis is 
a key function in the action of antidepressants,
9,30,32
 it is likely that the PrL region of 
mPFC, CA3, and DG, but not the IL region of mPFC and NAc, are involved in this 
drug’s action.  
The pharmacokinetic profile of ketamine in male C57/B6 mice has previously 
been reported. Its half-life in mouse plasma is approximately thirty minutes,
59 
indicating a possible rapid clearance from the body. The two stereoisomers of 
ketamine share similar pharmacokinetic profiles.
10
 Therefore, it is unlikely that the 
differential antidepressant effects noted here between R- and S-ketamine are due to 
differences in their pharmacokinetic profiles. 
S-Ketamine has an approximately 4-fold greater affinity for the NMDA 
receptor than the R-isomer.
10
 It is therefore, unlikely that this receptor plays a major 
role in the long-lasting effects of R-ketamine, although antagonism at this receptor 
may promote its rapid action. Possible interactions with other systems such as opioid 
receptors, sigma-1 receptor chaperones, or voltage-dependent ion channels may also 
mediate the antidepressant effects of ketamine.
5,10,23
 Nonetheless, further detailed 
studies on the molecular basis of R-ketamine’s actions are needed. 
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Clinical use of ketamine is limited due to its side effects. Unlike S-ketamine, 
R-ketamine does not appear to cause psychotomimetic effects, based on the lack of 
behavioral abnormalities (e.g., hyperlocomotion, PPI deficits) observed in rodents 
after treatment. A randomized study in healthy male volunteers (N=10) showed that 
subjective side effects were more pronounced for S-ketamine than R-ketamine.
60
 
Given that the loss of PV-positive cells contributes to the pathogenesis of 
schizophrenia,
51
 it is unlikely that R-ketamine induces psychotomimetic side effects in 
humans since, unlike S-ketamine, R-ketamine did not cause a reduction of 
PV-positive cells in the brain. Repeated use of ketamine can result in drug abuse in 
humans.
50
 In CPP tests, R-ketamine did not increase CPP scores in mice whereas 
RS-ketamine (racemate) and S-ketamine did so in a significant manner. Combined 
data points to R-ketamine being free of psychotomimetic side effects and abuse 
potential in humans.  
In conclusion, our study shows that a single dose of either of the two 
stereoisomers of ketamine can produce rapid antidepressant effects in the social defeat 
stress model of depression. However, unlike S-ketamine, R-ketamine can elicit a 
sustained antidepressant effect in this rodent model. Furthermore, it is likely that 
increased synaptogenesis in the PrL region of the mPFC, DG and CA3 of the 
hippocampus may mediate the sustained antidepressant response of R-ketamine. 
Finally, R-ketamine appears to be a potent, long-lasting and safe antidepressant, 
relative S-ketamine, since R-ketamine is free of psychotomimetic side effects and 
abuse liability.  
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CHARPTER II 
1. Background 
Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and 
serotonin–norepinephrine reuptake inhibitors (SNRIs), are used in the treatment of 
depression. However, approximately two- thirds of patients fail to achieve full 
remission using current drug therapies.
1
 The fast-acting antidepressant effects of the 
N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, have attracted serious 
attention after it was found that a single sub-anesthetic dose (0.5 mg/kg) of ketamine 
elicited a rapid antidepressant effect within 1-2 hours, in depressed patients, including 
those with treatment-resistant depression and treatment-resistant bipolar depression. 
Moreover, these beneficial effects persist for up to two weeks in some patients.
2
 
Ketamine (or RS-ketamine) is a racemic mixture containing equal parts of 
R-ketamine and S-ketamine (esketamine). Esketamine shows an approximately 3-4 
fold greater anesthetic potency and greater undesirable psychotomimetic side effects, 
compared with R-ketamine.
3
 This is related to the fact that esketamine has an 
approximately 4-fold greater affinity for the NMDA receptor relative to R-ketamine.
3
 
Previously, we reported that R-ketamine shows greater potency and longer lasting 
antidepressant effects than esketamine in animal depression models, including 
neonatal dexamethasone exposure, repeated social defeat stress and learned 
helplessness, and that unlike esketamine, R-ketamine does not induce 
psychotomimetic side effects.
4,5 
Deficits of parvalbumin (PV)-positive cells in the brain are associated with 
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psychosis and schizophrenia.
6,7
 Recently, we reported that a single dose of esketamine 
(10 mg/kg), but not R-ketamine (10 mg/kg), resulted in loss of PV-immunoreactivity 
in brain regions, such as the prelimbic (PrL) area of the medial prefrontal cortex 
(mPFC) and dentate gyrus (DG) of the hippocampus.
4
 In addition, repeated ketamine 
infusions induced rapid and long-lasting antidepressant effects in patients with 
treatment-resistant depression.
8
 Given that repeated intermittent use of ketamine is 
likely to result in psychosis, the present study was performed to examine whether 
repeated intermittent administration of ketamine enantiomers could affect 
PV-immunoreactivity in the mouse brain. 
2. Materials and methods 
Male adult C57BL/6 mice, aged 8 weeks (body weight 20–25g, Japan SLC, Inc., 
Hamamatsu, Japan) were used in this study. R-ketamine hydrochloride and 
S-ketamine (esketamine) hydrochloride were prepared by recrystallization of 
RS-ketamine (Ketalar
®
, ketamine hydrochloride, Daiichi Sankyo Pharmaceutical Ltd., 
Tokyo, Japan) and D-(-)-tartaric acid (or L- (+)-tartaric acid), as described previously 
(Zhang et al., 2014). Saline (10 ml/kg), R-ketamine (10 mg/kg), or esketamine (10 
mg/kg) was intermittently administered eight times once a week intraperitoneally 
(i.p.) into mice (n = 6). The dose of ketamine enantiomers was used as reported 
previously.
4,5 
Animals were housed under controlled temperatures and 12 hour 
light/dark cycles (lights on between 07:00–19:00 h), with ad libitum food (CE-2; 
CLEA Japan, Inc., Tokyo, Japan) and water. This study was carried out in strict 
accordance with the recommendations in the Guide for the Care and Use of 
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Laboratory Animals of the National Institutes of Health. The protocol was approved 
by the Chiba University Institutional Animal Care and Use Committee. 
One week after the final injection, mice were anesthetized with sodium 
pentobarbital (50 mg/kg) and perfused transcardially with 10 mL of isotonic saline, 
followed by 40 mL of ice-cold, 4% paraformaldehyde in 0.1%M phosphate buffer 
(pH 7.4). Brains were removed from the skulls and postfixed overnight at 4℃ in the 
same fixative. PV-immunohistochemistry was performed as previously reported.
4
 The 
samples ware then incubated for 24 h at 4℃ with rabbit polyclonal anti-PV antibody 
(1:2,500, Swant, Bellinzona, Switzerland). The sections were washed three times in 
TBS and then processed using the avidin-biotin-peroxidase method (Vectastain Elite 
ABC, Vector Laboratories, Inc., Burlingame, CA, USA). Sections ware incubated for 
3 min in a solution of 0.25 mg/mL DAB containing 0.01% H2O2. Then, sections were 
mounted on gelatinized slides, dehydrated, cleared, and cover slipped under Permount
Ⓡ(Fisher Scientific, Fair Lawn, NJ, USA). The sections were imaged, and the staining 
intensity of PV immunoreactivity in the mPFC (PrL, infralimbic (IL)), nucleus 
accumbens (NAc), hippocampus (CA1, CA3, DG) was analyzed using a light 
micro-scope equipped with a CCD camera (Olymups IX70, Tokyo, Japan) and the 
SCION IMAGE software package. Images were captured using a 100× objective with 
a Keyence BZ-9000 GenerationⅡmicroscope (Osaka, Japan). 
The data show as the mean ± standard error of the mean (S.E.M.). Analysis was 
performed using PASW Statistics 20 (formerly SPSS Statistics; SPSS). Comparisons 
between groups were performed using the one-way analysis of variance (ANOVA), 
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followed by post-hoc Bonferroni test. The P-values of less than 0.05 were considered 
statistically significant. 
3. Results 
One-way ANOVA demonstrated significant changes among all groups in the PrL 
(F2,15 = 9.474, P = 0.002) and IL regions (F2,15 = 6.544, P = 0.009) of mPFC, and CA1 
(F2,15 = 6.326, P = 0.01), CA3 (F2,15 = 8.133, P = 0.004) and DG (F2,15 = 10.95, P = 
0.001), but no effect in the NAc (F2,15 = 0.546, P = 0.59). Post-hoc Bonferroni testing 
revealed that repeated intermittent administration of R-ketamine did not affect the 
proportion of PV-immunoreactivity in any of the observed brain regions (Fig. 1A-1F). 
In contrast, repeated intermittent administration of esketamine significantly decreased 
the proportion of PV-immunoreactivity in the PrL and IL regions of the mPFC (Fig. 
1A and 1B) and all sub-regions (CA1, CA3, DG) of the hippocampus (Fig. 6F), but 
not in the NAc (Fig. 1C). 
4. Discussion 
Using PV-immunohistochemistry, we found that repeated intermittent dosing 
with esketamine, but not R-ketamine, elicited a significant reduction of 
PV-immunoreactivity in observed brain regions, including PrL and IL regions of 
mPFC, and CA1, CA3 and DG regions of hippocampus. These findings suggested 
greater safety for repeated intermittent dosing with R-ketamine relative to esketamine. 
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Ketamine exerts a robust and fast-acting antidepressant effect within 1-2 hours that 
can last for up to one week.
2
 Therefore, a schedule of repeated ketamine 
administration could provide effective management of depressive symptoms in  
Figure 1. Effect of R-ketamine and esketamine on the proportion of PV-positive 
immunostaining in the brain regions. Representative photomicrographs of 
PV-immunohistochemistry in the PrL (A) and IL (B) of mPFC, NAc (C), CA1 (D), CA3 (E), and 
DG (F) of hippocampus from animals of each group. Scale bar = 50 µm (A-C) or 200 µm (D-F). 
The data show the mean ± SEM (n = 6). *P < 0.05, **P<0.01 compared with saline-treated group. 
NS: not significant. 
 
patients with treatment-resistant depression. Accumulating evidence suggests that 
NMDA receptor hypofunction plays a role in the loss of PV-positive cells, a state 
 46 
 
associated with schizophrenia pathogenesis.
6,7,9
 Repeated administration of ketamine 
elicits gamma band oscillation abnormalities observed in schizophrenia patients.
10
 
Since esketamine has a 4-fold higher binding affinity to the NMDA receptor than 
R-ketamine,
3
 it is reasonable to accept that esketamine may have a greater propensity 
to induce both deficits in PV-positive cells and the emergence of psychosis in 
humans. 
This study has a limitation since the only one dose of ketamine’s enantiomers 
was used. Further dose-dependence studies should be performed to compare the 
effects of ketamine’s enantiomers in animal models. 
In conclusion, this study demonstrated that repeated intermittent administration 
of esketamine, but not R-ketamine, causes a significant loss of PV-immunoreactivity 
in mouse brain regions. Therefore, relative to esketamine, R-ketamine is likely to be a 
safer antidepressant in the treatment of depression. 
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